Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 301 to 325 of 1147 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
291 decreased norepinephrine biosynthetic process (GO:0042421) (R)-noradrenaline (CHEBI:18357) 528: Decreased, Synthesis of NE
434 decreased norepinephrine binding (GO:0051380) (R)-noradrenaline (CHEBI:18357) 848: Decreased, Binding of NE to NE receptors on GnRH neurons
727 decreased androgen biosynthetic process (GO:0006702) 11-Keto-testosterone (CHEBI:34133) 1756: Decreased, plasma 11-ketotestosterone level
257 decreased catalytic activity (GO:0003824) 17-beta-hydroxysteroid dehydrogenase 14 (PR:000008778) 482: Decreased, DHB4/HSD17B4
1137 increased regulation of steroid hormone biosynthetic process (GO:0090030) 17beta-estradiol (CHEBI:16469) 2402: Increased, estradiol (E2) production in ovaries
1139 increased increased circulating estradiol level (MP:0005182) 17beta-estradiol (CHEBI:16469) 2294: Plasma estradiol, increased
33 decreased 17beta-estradiol (CHEBI:16469)
34 decreased estrogen biosynthetic process (GO:0006703) 17beta-estradiol (CHEBI:16469)
967 decreased hormone biosynthetic process (GO:0042446) 17beta-Hydroxy-2-oxa-5alpha-androstan-3-one (CHEBI:79436) 1613: Decrease, dihydrotestosterone (DHT) levels
1029 increased hormone biosynthetic process (GO:0042446) 17beta-hydroxy-5alpha-androstan-3-one (CHEBI:16330) None
1033 increased androgen biosynthetic process (GO:0006702) 17beta-hydroxy-5alpha-androstan-3-one (CHEBI:16330) 2273: Dihydrotestosterone (DHT) levels, increased
430 decreased hydroxymethylglutaryl-CoA reductase activity (GO:0042282) 3-hydroxy-3-methylglutaryl-coenzyme A reductase (PR:000008636) 804: Inhibition, HMG-CoA reductase
185 decreased gene expression (GO:0010467) 3-hydroxyacyl-CoA dehydrogenase type-2 (PR:000008774) 140: Decreased, HSD17B10 expression
186 decreased 3-hydroxyacyl-CoA dehydrogenase activity (GO:0003857) 3-hydroxyacyl-CoA dehydrogenase type-2 (PR:000008774)
418 decreased catalytic activity (GO:0003824) 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (rat) (PR:P31214) None
520 decreased 3,3',5-triiodo-L-thyronine (CHEBI:18258)
575 increased 3,3',5-triiodo-L-thyronine (CHEBI:18258) 1116: Decreased, Triiodothyronine (T3) in tissues
712 decreased abnormal circulating hormone level (MP:0005418) 3,3',5-triiodo-L-thyronine (CHEBI:18258) None
711 decreased abnormal circulating hormone level (MP:0005418) 3,3',5'-triiodothyronine (CHEBI:28774) None
898 decreased decreased triiodothyronine level (MP:0005473) 3,3',5'-triiodothyronine (CHEBI:28774) 1003: Decreased, Triiodothyronine (T3)
352 increased 3',5'-cyclic AMP(1-) (CHEBI:58165) 693: Increased, cyclic adenosine monophosphate
406 decreased 4-hydroxyphenylpyruvate dioxygenase activity (GO:0003868) 4-hydroxyphenylpyruvate dioxygenase (rat) (PR:P32755) 766: Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme
1080 increased serotonin receptor signaling pathway (GO:0007210) 5-hydroxytryptamine receptor 1A (PR:000001161) 2308: Increased, stimulation of brain serotonin 5-HT1a, 5-HT2c receptors
1081 increased serotonin receptor signaling pathway (GO:0007210) 5-hydroxytryptamine receptor 2C (PR:000001168) 2308: Increased, stimulation of brain serotonin 5-HT1a, 5-HT2c receptors
164 increased signaling (GO:0023052) 5-hydroxytryptamine receptor 2C (PR:000001168) 9: Activation, 5HT2c